Retatrutide, Tirzepatide, Cagrilintide: comparison of metabolic mechanisms

The major families of metabolic receptors studied in research

Research on energy homeostasis has historically been organized around several families of G protein-coupled receptors, expressed particularly in the pancreas, hypothalamus, and brainstem. Three main themes consistently emerge in the literature on peptide analogs: the incretin axis (receptorsGLP-1 et GIPThe three main axes are the glucagon axis (GCGR receptor) and the amylin axis, a hormone co-secreted with insulin that acts on distinct receptors related to the calcitonin family. These three axes do not overlap: each modulates different intracellular signaling pathways (cAMP, PKA, ERK) and distinct neuronal populations. It is this diversity of molecular targets that has led researchers to design molecules capable of acting on one, two, or even three receptors simultaneously, in order to study the combined effects compared to an isolated action.

Tirzepatide, a dual GLP-1/GIP agonist

Le TirzepatisTirzepatide (LY3298176) is being studied as a dual agonist of the GLP-1 and GIP receptors. Its peptide sequence is derived from the backbone of native GIP, modified to acquire functional affinity for the GLP-1 receptor while retaining activity on the GIP receptor. In research models, this dual activation allows for the observation of combined effects on glucose-dependent insulin secretion (via GLP-1) and on lipid metabolism and insulin sensitivity in adipose tissue (via GIP), two pathways which, when activated in isolation, produce different response profiles in the models studied. The scientific interest of tirzepatide lies precisely in this potential synergy between two receptors of the incretin family, which has opened a new field of investigation compared to the single GLP-1 agonists that have been studied for longer.

Retatrutide, a triple agonist (with the addition of glucagon)

Le Retatrutide(LY3437943) takes the molecular design a step further by adding a third target: the glucagon receptor (GCGR). It is therefore a triple unimolecular agonist, active on GLP-1, GIP, and glucagon. The integration of glucagon activity is particularly studied for its reported role in regulating energy expenditure and hepatic glucose and lipid metabolism, mechanisms distinct from the central appetite regulation associated with GLP-1 receptors. In preclinical research, this triple agonist architecture allows for modeling interactions between three signaling pathways usually studied separately, and serves as a tool to understand how the combined modulation of incretin and non-incretin receptors influences metabolic markers measured in vitro and in vivo.

Single, double and triple agonism: what is the fundamental difference?

The distinction between single, dual, and triple agonism does not simply refer to an addition of potency on the same target, but rather to the engagement of biologically distinct receptors. A single agonist (like the historical GLP-1 analogs) activates only one signaling pathway. A dual agonist, like Tirzepatide, engages two receptors with partially different tissue expression profiles. A triple agonist, like Retatrutide, adds a third pathway whose cellular effectors (adenylate cyclase, protein kinase A, MAPK pathways) partially overlap with the first two. This multi-target architecture constitutes an experimental model for studying the interaction effects, additive or otherwise, between several metabolic regulatory systems within a single molecule.

Cagrilintide, another route: amylin

Le CagrilintideCagrilintide employs a completely different mechanistic pathway than the two previous molecules. It is a long-acting analog of amylin, a peptide hormone naturally co-secreted by pancreatic beta cells alongside insulin. Unlike the GLP-1/GIP/glucagon systems, which belong to the secretin-like peptide receptor superfamily, the amylin receptor results from the association of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMPs). This receptor-accessory protein architecture confers pharmacological properties to the amylin signal that are distinct from those of incretins, particularly at the level of brainstem structures involved in the integration of peripherally originating satiety signals. In research, cagrilintide is therefore used as a tool to explore a complementary, non-redundant signaling pathway compared to GLP-1, GIP, and glucagon receptor agonists.

Comparative table of mechanisms

• Tirzepatis— molecular targets: GLP-1 and GIP receptors; family: incretins; nature of agonism: dual.
• Retatrutide— molecular targets: GLP-1, GIP and glucagon receptors (GCGR); family: incretins and glucagon; nature of agonism: triple.
• Cagrilintide— molecular target: amylin receptor (CTR/RAMP complex); family: amylinergic, distinct from incretins; nature of agonism: simple, on a non-incretin pathway.

This table highlights that the number of receptors involved (single, double, triple) is not sufficient to compare molecules: the nature of the receptors is as important as their number. Cagrilintide, although a single-target molecule, acts on a system that is biologically independent of the other three, making it a prime candidate for combined research protocols.

Combinations as a research focus

One current focus of research in metabolic physiology is the experimental co-administration of molecules targeting non-redundant pathways, particularly the combination of a GLP-1 receptor agonist (or dual/triple agonist) with an amylin analog. The underlying mechanistic hypothesis is that the simultaneous activation of the incretin and amylinergic pathways, which partially converge at brainstem circuits while utilizing distinct receptors, could produce response profiles different from those observed with each molecule taken separately. These combined research protocols, still in the experimental stage, aim to better characterize the interactions between signaling systems rather than establish a hierarchy of efficacy among compounds. They illustrate the general logic of this research field: understanding how distinct molecular pathways interact within the same model organism.

In summary, Tirzepatide, Retatrutide, and Cagrilintide are three complementary molecular tools for laboratory research on metabolic regulation: the first two explore the progressive extension of agonism within the incretin and glucagon families, while the third opens a completely distinct mechanistic pathway via the amylinergic system. Each compound is supplied with its own Certificate of Analysis (COA) per batch, with quantified HPLC purity (published Janoshik reports for retatrutide and cagrilintide), for strictly experimental and non-clinical use.

---

The products mentioned are intended exclusively for scientific laboratory research. They are not intended for human or animal consumption, nor for medical, veterinary, or therapeutic use. No dosage advice or health claims are made. Sale restricted to adults.